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1. Introduction  
The neurotransmitter Dopamine (DA) exerts a dual function in the striatum (STR), the latter 
comprising the caudate and putamen nuclei, the main structures in the central nervous 
system from which it is released. During the last 50 years, numerous studies have 
highlighted the role of DA in sensory/motor loops. Along with a phasic function exerted in 
synaptic or close apposition structures, a modulatory role for extracellular DA has also been 
demonstrated based on the slow and tonic extracellular diffusion of the amine. This duality 
is probably supported by a metabolic polymorphism, particularly of the release mechanism. 
The present chapter focuses on works carried out in vivo over the last two decades on the 
control of DA homeostasis in the STR during normal and pathological conditions. It is now 
generally accepted that the level of extracellular DA is not simply the consequence of 
dribbling from the synapse after phasic (firing-dependent) overflow but is maintained 
through tonic, largely non–synaptic, regulatory processes.  
The duality of DA release in vivo will first be described. An example of an experimental 
situation allowing this situation to be characterized will be given, followed by a brief 
overview of the relevant literature from the last three decades. 
The tonic regulatory process remains incompletely understood and still requires thorough 
analysis. In recent years, in vivo and in vitro studies have led to the development of 
theoretical models based on the concept of the reversion of the well-known uptake 
mechanism involving the DA transporter protein (DAT). In particular conditions, DAT 
could be involved in the control of the extracellular DA concentration through its ability to 
perform what is called reverse DA transport (DA-RT). Psychotropes from the amphetamine 
family are known to induce the release of DA through this mechanism, but the physiological 
involvement of DA-RT has rarely been adressed.  
A large number of regulatory processes have been described concerning tonic DA release. 
Only two aspects of these regulatory processes will be considered here. Specific experiments 
devoted to showing the role of DA synthesis and extracellular calcium ions will be described 
and discussed.  
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The two first paragraphs will be devoted to the duality of normal DA neurotransmission. It 
is however crucial to understand how the two different mechanisms of release (tonic and 
phasic) could maintain their equilibrium in pathological situations. Numerous animal 
models of neurodegeneration have been created. To date, only situations mimicking the 
early phases of parkinsonian neurodegeneration have been used to explore this equilibrium. 
Original results will also be presented here. These will provide new information on the 
regulatory modulation of the tonic and phasic release occurring during the initial pre-
symptomatic compensatory phases of Parkinson’s disease. 
2. The dual DA release process 
The extracellular DA concentration in the caudate nucleus could be relevant to something 
other than the electrical activity of dopaminergic cells. Increased DA release was even 
observed in the STR under experimental conditions that decreased cell firing in the substantia 
nigra (SNc, Romo et al., 1986). Since the first proposal by Raiteri et al. (1977) that DA could be 
released by a calcium-independent and carrier-mediated process, numerous authors have 
claimed that the firing-dependent release of DA does not explain all the reported alterations in 
the extracellular DA concentration and that an additional release mechanism must exist (Liang 
and Rutledge, 1982; Parker and Cubeddu, 1986; Vizi and Labos, 1991). In 1991, A. Grace 
gathered relevant data and proposed the presence of two modes of release of the amine in the 
STR (Fig 1), one ‘phasic’, taking place within the millisecond range, and controlled by The 
firing running on DA axons, and a ‘tonic’ mode, taking place over minutes or hours and 
mainly dependent on various direct influences on the DA terminals including that of 
Glutamate (GLU). Using differential pulse amperometry (DPA) simultaneously associated 
with local superfusion and HPLC detection we observed this dual release of DA in response to 
axonal stimulation and the application of GLU agonists (Fig. 2; Olivier et al., 1995). 
Amphetamine
Phasic DA release
Exocytose
Firing dependent
Calcium dependent
Quantic
Tonic DA Release
Reverse transport (DA-RT)
Firing independent
Ca++ Channel independent
Na+ gradient dependent
GLU dependent
DA
TYR
TrP
Vesicles
 
Fig. 1. The dual release of DA through vesicles exocytose or DA transport (TrP). 
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2.1 Spontaneous and evoked DA release 
Dual release can be demonstrated by the simultaneous use of two probes. DPA uses a 
carbon fiber electrode to detect the DA released following stimulation of the DA axons in 
the Medial Forebrain Bundle (MFB) in the lateral hypothalamus. Every 4 minutes, a 20-
second stimulation-train pulse produces a large increase in the amperometric signal in the 
STR that is strictly restricted to the stimulation period (Fig. 2, Olivier et al., 1995). The 
amplitude of the peaks that occur is roughly constant over time. As discussed elsewhere by 
Gonon (1988) and Suaud-Chagny et al. (1992), the increase in the oxidation current under 
these conditions is likely to be mainly due to the DA released, despite the fact that some of 
this increase could be due to dihydroxyphenyl acetic acid (DOPAC), the first DA metabolite. 
Simulation of the MFB alters the differential oxidation current but is ineffective in terms of 
the amount of regional extracellular basal DA measured through a cannula close to the 
probe used for DPA. The DA collected through the superfusion system originates from a 
region considerably larger than the carbon fiber. The carbon fiber is only sensitive to events 
occurring in the range of µm from its suface whereas the superfusing probe collects 
diffusing molecules from within several hundreds of microns. Differences also arise from 
the duration of the measurements. Stimulation of the MFB only lasts for a short period of the 
collection time (here 0.08%). Given this short period of time, any increase in the release of 
the amine remains undetectable in the superfusing fluid. The superfusing methods are 
particularly useful for detecting ‘regional’ fluctuations whereas voltammetry reports local 
events. 
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Fig. 2. The effect of MFB stimulation on tonic (up) and phasic down DA release 
Superfusion in the presence of cadmium ions: 
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To block the voltage-dependent calcium channel, 100 µM cadmium was added to the 
artificial LCR supplying the cannula. This treatment blocks the stimulation-evoked release 
of DA detected using DPA (Fig. 3). The same effect can be obtained using 1 mM cobalt (not 
shown) in place of cadmium and remains unchanged in the presence of 0.5 µM GBR12909, a 
DAT inhibitor. Surprisingly, in the presence of cadmium or cobalt the amount of DA 
detected in the superfusing fluid greatly increased during the first 40 minutes of application 
(Fig. 3). Over this period of time, the DA collected fell below control values. When 0.5 µM 
GBR12909 was simultaneously added with cadmium, no further increase in the amount of 
DA was detected in the superfusing fluid. 
Min.
Min.
 
Fig. 3. Blockade of calcium channels via local application of cadmium 
Local superfusion with GLU agonists: 
Addition of the GLU agonists NMDA (1 mM) and kainate (0.1 mM) to the superfusing fluid 
increased the amount of DA collected through the push-pull cannula and reduced the 
amperometric signal evoked by MFB stimulations (Fig. 4). The reduction in the 
amperometric signal was not counteracted by the presence of 0.5 µM GBR12909. In contrast 
the increase in the spontaneous release measured through the cannula in response to 
NMDA or Kainate application completely disappeared.  
2.2 From quantal release to reverse transport, the duality of DA release 
These experimental observations constitute the most simple and direct evidence of the 
presence of a double mechanism of release of DA from the DA terminals in the STR. A large 
set of complementary data will now be briefly reviewed.  
Can DA homeostasis be regulated by the firing-evoked synaptic release of DA? 
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Min. Min.
 
Fig. 4. The dual effect of GLU receptor blockade 
The first evidence that regional extracellular DA and synaptic DA are not governed by the 
same mechanism is derived from the fact that although they should vary in parallel, that is 
clearly not the case. Many observations based on voltammetry have confirmed the ability of 
DA axons transiting through the MFB to carry an electrical potential, since an increase in 
extracellular DA can occur in response to electrical stimulations of the MFB (see above, Ewing 
and Wightman, 1984; Ewing et al., 1983; Gonon and Buda, 1985; Kuhr et al., 1986; Stamford et 
al., 1986). The voltammetric approach can only be used in a very restricted region of the space 
due to the size of the probes used. When using methods suitable for larger regions (micro-
dialysis, push-pull cannula systems),  it became clear that to alter DA levels in the STR, 
stimulation of the DA afferents required axonal recruitment and stimulation frequencies 
outside the physiological range (Grace, 1991; Olivier et al., 1995). Indeed, more than 60–70% of 
DA varicosities were found to be asynaptic, and DA synapses represent only about 1.8–7% of 
all striatal synapses (Decarries and Mechawar, 2000). Even if DA cell firing can elicit DA 
release in the STR for a brief period of time, the synaptic DA released may not be the only 
contributor to extracellular DA levels and would not be expected to be responsible for 
homeostatic DA control in the STR (Grace, 1991; Levi and Raiteri, 1993; Olivier, 1995). DA 
concentration is probably only partially monitored by nigral DA firing cells and DA 
homeostasis is unlikely to be controlled by spill-over of the amine from synaptic events.  
Using DAT to re-visit DA release: DA-RT 
It has been known for many years that exocytosis is not the only outward process of the 
neurotransmitter exchange between neurons and the extracellular space (Stein, 1967). 
Regarding monoamines, several models in the peripheral nervous system have been 
proposed that are generally based on exchange diffusion (Bogdanski and Brodie, 1969; 
Paton 1973a, 1973b). Concerning the release of DA in the central nervous system, DAT was 
thought to be partly involved in DA release by some authors (Marchi et al., 1985; Olivier et 
al., 1995; Raiteri et al., 1979) and the mechanism of this carrier-mediated release came from 
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observations on psychostimulants and amphetamine-like substances (Butcher et al., 1988; 
Fisher and Cho, 1979; Leviel, 2001; Levi and Raiteri, 1993; Nash and Brodkin, 1991). In this 
process, transmitter molecules are transported outside the cell, most likely via an exchange-
diffusion process. This mode of transfer has been extensively studied and various 
mathematical models have been proposed over the course of the last four decades (Chubb et 
al., 1972; Stein, 1990, for a review; Thoenen et al., 1969; Wheeler et al., 1993; Ziance and 
Rutledge, 1972).  
During the 1980s, several studies were devoted to the regulatory mechanism of DA release 
in the STR and the substantia nigra pars reticulate (SNr). Particular attention was given to 
the control of striatal release, which is known to be regulated by GLU. It appeared that, in 
addition to a spike-mediated DA efflux, GLU-induced amine overflow could occur 
independently of any sodium or calcium transfer. This would mean that some of the 
extracellular DA, the NMDA-mediated DA that is released, is not dependent on the firing of 
DA neurons (Carter et al., 1988; Cheramy et al., 1986; Giorguieff et al., 1977; Jhamandas and 
Marien, 1987). The NMDA-mediated release of DA even remained unchanged when the 
nigrostriatal pathway was blocked with lesions or tetrodotoxin (Keefe et al., 1992, 1993). 
Recently, using voltammetry associated with electrochemical detection, the same type of 
observation was again reported (Borland and Michael, 2004). Such observations had already 
led Anthony Grace to propose, at the beginning of the 1990s, that DA could be released in 
the STR following two different types of mechanism (Grace, 1991): first, the firing-
dependent exocytosis of quantal amounts of amine previously stored in specific pools, and, 
simultaneously, NMDA-mediated release.  
More recently, Falkenburger et al. (2001) confirmed the existence of DA-RT in slices from rat 
SNc. This explained at least part of the dendritic release of DA. The presence of the somato-
dendritic release of DA from the nigrostriatal cells has been known for many years 
(Cheramy et al., 1981) but the mechanism of this release was, and remains, an open 
question. As in the experiment conducted by Olivier and co-workers, the demonstration was 
based on the use of DAT inhibitors (GBR 12909, GBR 12935) that were able to block the 
GLU-induced release of DA. In a more recent study (Opazo et al., 2010), the voltammetric 
current corresponding to outward moving DA was increased by adding 1-
Aminocyclopentane-trans 1,3 dicarboxylic acid (trans ACPD), an activator of the GLU group 
I mGLUR, to rat nigral slices. This confirmed the role of GLU in this type of DA release. It 
was also demonstrated that protein kinase C (PKC) activation produced a robust increase in 
external DA levels that was reversibly inhibited by GBR 12935, a well-known DAT inhibitor. 
These observations confirmed the identities of the two DA releasing processes. These 
observations were also made in vitro in an engineered neuroblastoma cell line (SH-SY5Y 
cells) stably expressing DAT (Opazo et al., 2010).  
The two release processes act simultaneously in both the SNc and the dSTR. As mentioned 
above, and given the various morphologies of DA neurons (Arluison et al., 1978; Gauthier et 
al., 1999; Gerfen et al., 1987; Prensa et al., 2000), the possibility that some types of DA 
neurons could be specialized in one or the other of the release modes cannot be excluded. 
For instance, it is noteworthy that mesencephalic DA neurons from the ventral tegmental 
area poorly express DAT (Blanchard et al., 1994; Ciliax et al., 1999; Mengual and Pickel, 
2004; Nirenberg et al., 1996; Sesack et al., 1998). The dual release function of DA neurons 
may not be equally distributed throughout the whole population of DA cells. The term 
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‘volume transmission’, developed in the 1980s (Agnati et al., 1986) and recently used to 
characterize DA neurotransmission, does not refer to a mode of release but rather to a mode 
of extracellular transmission. The terms ‘phasic release’ and ‘tonic release’ most frequently 
refer to the pattern of discharge of the DA axons (regular or bursting). The most appropriate 
terms that have emerged to date to qualify the present types of neurotransmitter release are 
‘quantal’ for the firing-dependent process and ‘reverse transport’ (DA-RT) or ‘lateral release’ 
for the carrier-mediated mechanism. We also use the term ‘lateral release’ to refer to the 
non-synaptic localization of this mechanism, due to the extra-synaptic position of the DA 
transporter. In this case, ‘axial release’ could refer to synaptic transmission. 
3. Regulatory mechanisms 
It has already been shown that the extracellular level of calcium (Ca++) ions has an important 
influence on neurotransmitter release (Katz and Miledi, 1970; Augustine et al., 1987; Smith and 
Augustine, 1988; Mulkey and Zucker, 1991) and on enzyme activities (Kapatos and Zigmond, 
1982; El Mestikawy et al., 1983; Haycock, 1993). Since transient increases in Ca++ within nerve 
terminals are spatially restricted (Lipscombe et al., 1988; Meldolesi et al., 1988; Miller, 1991) it 
may be hypothesized that Ca++ independently affects multiple processes within the different 
ultrastructural compartments of the nerve terminal. The metabolism and release of DA in the 
STR constitute an appropriate experimental model with which to investigate the potentially 
distinct effects of Ca++. In the dopaminergic neurons DA synthesis depends on the activity of 
tyrosine hydroxylase (TH), the rate-limiting enzyme in its synthetic pathway (Levitt et al., 
1965). This enzyme is activated by phosphorylation under the control of various protein 
kinases, including two Ca++-dependent ones, the Ca++-phospholipid-dependent protein 
kinases (PKC) and the Ca++-calmodulin-dependent protein kinase (PKII) (El Mestikawy et al., 
1983; Albert et al., 1984; Zigmond et al., 1989; Haycock, 1993). 
Below we will present further data about the dual control exerted by Ca++ ions on DA 
synthesis and on DA-releasing processes. The apparent challenge between synthesis and 
release in the effects of Ca++ is coming from the fact that DA-RT acts on cytoplasmic DA , 
unlike exocytosis, which affects a previously vesicularysed stored pool of DA. It can thus be 
hypothesizd that DA-RT should be more sensitive to those treatments affecting synthesis. 
3.1 Synthesis, calcium ions and DA release – Experimental report 
We describe here the only method known to evaluate DA synthesis and release 
simultaneously in vivo in anesthetized rats. The method is based on the measurement of the 
specific activity (DAsa) of the DA released during continuous superfusion of the tissue with 
the tritiated DA precursor, [3H]tyrosine. It was previously observed that the neosynthesized 
amine is released preferentially to an oldly stored pool. Taking advantage of this metabolic 
specificity, it can be postulated that: 1) increased DAsa during higher levels of release reflects 
enhanced synthesis and 2) decreased DAsa associated with increased levels of release reveals 
the involvement of stored amine (vesicular) and suggests reduced or insufficient synthesis. 
The DOPAC efflux is also considered to be a robust index of DA synthesis (Zetterström et 
al., 1988; Leviel et al., 1989). In other words, any treatment reducing synthesis should reduce 
cytoplasmic DAsa and the DOPAC efflux. In contrast, any treatment activating synthesis 
should elevate DAsa and the DOPAC efflux.  
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Fig. 5. Superfusion with CSF from which Ca++ was omitted 
Superfusion with calcium-free medium and α-methyl para-tyrosine (α-mpt) 
We already know that local superfusion with the calcium channel blockers cadmium and 
cobalt enhances regional DA release and blocks firing-induced exocytosis. Removing Ca++ 
ions from the superfusing medium (Ca0) led to a sharp decrease in DA release, stabilizing at 
around 30% of the basal value after about 80 min. This effect was accompanied by a 
lowering of the specific activity of DAsa and of [3H]DOPAC (Fig. 5). The addition of α-mpt, a 
TH inhibitor, did not modify the effect of Ca0 treatment: the DA collected in each 20-minute 
fraction also stabilized at around 30% of the spontaneous values (Fig. 6). These two effects 
were thus not additive, and the lowering of the DAsa produced by superfusion with Ca0 was 
of the same amplitude as that observed in the α-mpt treatment. This observation strongly 
suggests that the main effect of Ca0 could be the inhibition of DA synthesis (Olivier et al., 
1999). 
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Fig. 6. The inhibition of DA synthesis during superfusion in the absence of Ca++ 
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Superfusion with calcium ionophore (A23187): The forced entry of calcium 
Adding the Ca++ ionophore A23187 (1 µmol/l) to the superfusing fluid for 20 min had no 
effect on the spontaneous release of DA or DAsa (Fig. 7). However, an increase in DOPAC 
(25%) was associated with a 50% increase in the [3H]DOPAC concentration. 
It is possible to evaluate the effect of the calcium ionophore A23187 on DA synthesis ‘in 
vivo‘. A high dose of amphetamine can be superfused to produce the maximum overflow of 
the intraterminal DA. Thus 1 hour after administering 20 min of 1 mmol/l amphetamine, 
the total intraterminal DA had increased, particularly the DAsa (Olivier et al., 1999). This 
demonstrates a large increase in synthesis during this period of time. 
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Fig. 7. Superfusion with the Ca ionophore A23187 increases DA synthesis and DOPAC 
efflux 
3.2 The effect of extracellular calcium ions on DA-RT 
The above observations confirm that Ca++ ions are involved in different steps of DA 
metabolism, including not only the processes of release (Augustine et al., 1987) but also 
synthesis (Kapatos and Zigmond, 1982; El Mestikawy et al., 1983; Haycock et al., 1984). We 
have not directly measured the enzymatic activity of TH, but alterations in synthesis were 
revealed by the dynamic variations in DAsa and the [3H]DOPAC efflux. Indeed the DAsa can 
be used as an index of DA synthesis (Herdon et al., 1985) since the newly synthesized DA 
has a higher specific activity than the stored amine (Leviel et al., 1989). [3H]DOPAC might 
also be considered as a good index of amine synthesis according to many authors (Herdon 
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et al., 1985; Soares-Da-Silva, 1987; Zetterström et al., 1988; Leviel et al., 1989; Soares-Da-Silva 
and Garrett, 1990a, 1990b), who have  proposed that extracellular DOPAC originates from 
an unreleased and recently synthesized pool of dopamine. 
Ca++ ions in the regulation of DA synthesis: 
Removal of Ca++ from the superfusing fluid induced a large decrease in DAsa and in 
[3H]DOPAC efflux, suggesting reduced DA synthesis. Futhermore the addition of a TH 
inhibitor, namely α-mpt, to a Ca++-free superfusing fluid did not further decrease the DAsa 
or the [3H]DOPAC, suggesting that the activity of TH is already maximally inhibited by 
Ca++ removal. TH activity could be inhibited by a rise in DA feedback inhibition resulting 
from the lowering of Ca++-dependent exocytosis (Leslie et al., 1985; Zucker and Lando, 1986; 
Westerink et al., 1988). However, the intracellular accumulation of DA should result in 
increased DOPAC efflux, which was not observed. Conversely, the reduced DAsa revealed 
that even to maintain a low rate of DA release, stored amine (with a low specific activity) 
has to be involved, showing that in the absence of extracellular calcium ions, DA synthesis is 
unable to sustain the lower DA release (30% of the control value). 
Superfusion without Ca++ in the CSF appears to be able to reduce synthesis. Forced Ca++ 
entry could have the opposite effect. Indeed a low dose of the Ca++ ionophore A23187 (1 
µmol/l) slightly increased [3H]DA and [3H]DOPAC efflux, suggesting an increase in DA 
synthesis (Fig. 7). Such activation of synthesis was confirmed by the potentiation of the 
amphetamine-induced [3H]DA release that followed pretreatment with A23187 1 µmol/l 
(Olivier et al., 1999). 
This set of simple data is consistent with the concept that moderate Ca++ entry is positively 
coupled with DA synthesis and that its absence from the extracellular medium is negatively 
coupled with DA synthesis (Kapatos and Zigmond, 1982; El Mestikawy et al., 1983; Haycock 
et al., 1984). 
Ca++ ions in the regulation of DA-RT: 
Surprisingly, in vivo blockade of the Ca++ ion channel with Cd++ ions activates DA-RT from 
the DA terminals, an effect that was inhibited by further application of GBR 12909, a DAT 
inhibitor. The mechanism by which Cd++ affects DA-RT is not clear. For a long time, reversal 
of the Na+ gradient was proposed to reverse DA transport (Roth et al., 1976; Amejddki-Chab 
et al., 1992; Levi and Raiteri, 1993; Okada et al., 1990). It was also proposed by Olivier et al. 
(1999) that Cd++ indirectly alters DA-RT via Na+/K+ ATPase activity, a hypothesis also 
proposed for the action of AMPh (Khoshbouei et al., 2003; Pal et al., 1993).  
After applying a Ca++ ionophore, A23187, DA synthesis increased. With the classical model 
used for DA-RT of an exchange diffusion process, it is clear that the cytosolic DA constitutes 
the direct substrate for internal DAT-sites, regardless of its affinity. Thus, from these 
experiments, and despite the fact that DA-RT can be considered as being firing-
independent, many observations during the last decade have confirmed indirect calcium 
action on DA-RT (Fog et al., 2006; Gnegy et al., 2004; Kantor et al., 2001; Page et al., 2004). 
Numerous reports highlight the role of Ca++ in the amphetamine-dependent DA-RT. The 
Ca++ chelator BAPTA-AM reduced amphetamine-induced DA efflux as measured by 
amperometry. A particularly interesting observation was that superfusion of rat striatal 
slices with 50 µM BAPTA-AM suppressed the amphetamine-induced release of endogenous 
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DA. However, the same treatment had no effect on basal DA in the absence of AMPh. These 
studies demonstrated that AMPh-induced and DAT-mediated currents producing substrate 
efflux require internal Ca++ release from intracellular stores and that amphetamine can 
stimulate dopamine efflux by regulating cytoplasmic Ca++ levels (Gnegy et al., 2004). It has 
also been shown that Ca++/calmodulin-dependent protein kinase-II (CaMKII) plays a key 
role in the amphetamine-mediated efflux of DA in heterologous cells and dopaminergic 
neurons. CaMKII binds to the distal C terminus of DAT and co-localizes with DAT in 
dopaminergic neurons. The distal serines of the N terminus of DAT were phosphorylated by 
CaMKII in vitro and the mutation of these serines eliminated the stimulatory effects of 
CaMKIIa. A mutation of the DAT C terminus, impairing CaMKIIa binding, also impaired 
AMPh-induced DA efflux. Thus, it was suggested that the binding of CaMKIIa to the DAT C 
terminus facilitates phosphorylation of the DAT N terminus, which is responsible for the 
AMPh-induced dopamine efflux (Fog et al., 2006).  
A non-amphetaminic effect of CaMKII was also reported. Pseudo-phosphorylation of the 
hDAT N-terminal serines (S/D mutation), which appear to be phosphorylated by CaMKII, 
is largely able to evoke the reverse transport of DA even in unclamped cells, i.e. at resting 
membrane potential. This showed that activation of this enzymatic system (DAT) constitutes 
a mechanism of release by itself, even in the absence of amphetamine or any exogenous 
trigger. CaMKII is the most abundant kinase in the brain and could play a role in the 
regulation of various neurotransmitters (Colbran et al., 2003; Griffith, 2004). It is well known 
that local increases in Ca++ concentration and the CaMKII complex interact with the 
transduction of several neuronal signals, whether from DA neurotransmitters or not. 
Numerous proteins, such as the NR2B subunit of the NMDA receptor, could be involved in 
tonic release processes. It was recently proposed that tonic hyperactivity of the GLU 
afferents to the dopaminergic striatal terminals could maintain tonic-activated DA overflow 
in the rat STR following a 6-OHDA lesion of the SNc (Dzahini et al., 2010), and mechanisms 
such as those presently known to be evoked could be responsible for the effects observed. 
The same type of tonic hyperactivity could also be present in the mesencephalic region of 
the SNc. Sustained hypertonic GLU neurotransmission is often observed and reported in 
experimental and natural situations of neuro-degeneration, and could maintain secondary 
amine overflow without immediate consequences, but cause insidious degeneration. 
The main finding of recent reports about the regulatory processes of the DAT protein is the 
complete dissociation between inward (uptake) and outward (release) efflux. Untill recently 
DAT was considered to be an exchange diffusion system with a stoichiometric equilibrium 
linking the two functions. It is now clear that this concept should be revisited and that the 
inward regulatory processes differ from the release mechanism.  
In summary, three steps in DA metabolism occur to determine the extracellular DA 
concentration: synthesis, exocytosis and reverse transport (fig.8). Directly or indirectly, Ca++ 
ions modulate each of these. Thus carrier-mediated release (DA-RT) appears to be indirectly 
and negatively coupled with calcium entry, whereas synthesis and exocytosis are directly 
and positively coupled with Ca++ entry.  
3.3 Intraterminal DA metabolism: From synthesis to release 
The observations presented here and the numerous reports about DA synthesis, storage and 
release have enabled the proposal of a general model of the striatal DA terminal in 
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physiological conditions (Leviel et al., 1989). As mentioned above, components of this model 
may be attributed to different DA neurons. In the model presented in Fig. 8, a central pool of 
cytosolic DA constitutes the central point of the functional organization. Three input and 
four output routes are then described. The major way of supplying this central pool is via 
DA synthesis. A secondary supply mechanism could involve the intraterminal egress of DA 
from the vesicular storage pool. The third input comprises DA uptake transport.  
The first and major output of cytoplasmic DA involves the formation of DOPAC by the MAO 
enzyme. The second use of cytoplasmic DA involves terminal overflow through DA-RT. A 
small proportion of the synthesized DA is vesicularized in a neosynthesized pool constituting 
the preferentially releasable compartment of the amine, and is released by exocytosis. Some of 
this vesicularized amine supplies a storage compartment (old stored DA). 
This model takes into account the different mechanisms of DA release and DA metabolism 
that can be independently regulated. For example, reduced exocytotic release (by the 
blockade of calcium channels) can be accompanied by increased DA-RT, leading to an 
increase in extracellular amine. Thus even if the depolarization of DA axons is clearly 
responsible for exocytotic DA release, the preterminal influences could lead to secondary 
release that is differentially regulated, producing the paradoxical observations that are often 
reported (Leviel et al., 1989).  
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Fig. 8. The four-compartments model of intraterminal DA metabolism including dual 
release  
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4. Evolving DA release with DA cell degeneration 
4.1 Progressive DA denervation of the STR enhances DA transport in synaptosomal 
preparations  
Why address the consequences of DA cell degeneration?  So far we have described the 
equilibrium between two mechanisms that release DA, but only one of these is likely to be 
able to maintain DA homeostasis in the extracellular space. For a long time it was thought 
that the progressive degeneration of the DA cells of the SN, such as observed in 
Parkinson’disease (PD), is accompanied by the preservation of the DA concentration in the 
STR, a region that is innervated by DA axons. Basic observations have ascertained that DA 
metabolism is activated in spared dopaminergic terminals of the partially denervated STR. 
Both increased DA synthesis and reduced storage capacity were recurrently reported (see 
Zigmond et al., 1990 for a review). This was considered to be the possible cause of the 
unmodified (or even sometimes increased) extracellular DA level in this region (Stackowiak 
et al., 1987; Altar and Marien, 1989; Espino et al., 1995; Dentresangle et al., 2001; Dzahini et 
al., 2010). Nevertheless, no changes in either the firing pattern or the efficacy of release were 
observed in nigral DA cells following a moderate partial lesion (Hollerman and Grace, 1990; 
Dentresangle et al., 2001). On the contrary, spared DA neurons were described as 
hypoactive and pre-apoptotic (Pasinetti et al., 1989). This adaptation is unlikely to be the 
result of the electrical hyperactivity of the surviving nigral DA cells. 
Extracellular DA is taken up into dopaminergic terminals. In partially lesioned rats, the 
long-term reduction of this DA uptake may allow more diffusion in tissues (Snyder et al., 
1990; van Horn et al., 1992; Gerhardt et al., 1996). This hypothesis is reinforced by the fact 
that the depolarization of cells bearing the DA transporter reduces their ability to take up 
extracellular amine (Roth et al., 1976; Zahniser et al., 1998). GLU neurotransmission could be 
involved in this process. Indeed GLU is responsible for tonic membrane depolarization in 
CP (Wilson et al., 1995) and GLU neurotransmission is known to be hyperactive following a 
partial lesion (Lindefors and Ungerstedt, 1990; Samuel et al., 1990; Iwasaki et al., 1992; 
Wullner et al., 1994). 
Reduced DA uptake due to a reduced number of DA terminals is however unable to 
account for the maintained dopaminergic function as the extracellular DA concentration 
should also be correlated with a reduction in the number of release sites. No changes in the 
number of uptake sites per neuron were reported and the binding of the transporter ligands 
was even considered to be a good index of the terminal depopulation (Maloteaux et al., 
1988; van Horne et al., 1992). Thus normal or increased levels of extracellular DA, associated 
with a reduced number of dopaminergic terminals, imply an increased release/uptake ratio 
per terminal. GLU neurotransmission in the STR may mediate this increase. GLU was 
reported to increase DA synthesis (Desce et al., 1992; Fillenz, 1993; Castro et al., 1996), to 
activate DA release (Giorguieff et al., 1977; Cheramy et al., 1986; Leviel et al., 1990; Keefe et 
al., 1992) and to reduce DA uptake (Lin and Chai, 1998). The mechanism by which basal DA 
release is altered is however poorly understood. In the absence of any change in DA cell 
activity, alterations should involve DA-RT. This concept of activation of the DA metabolism 
through local GLU-dependent activation of DA-RT from the striatal DA terminal in 
response to the DA cell depopulation is widely debated. The following paragraph addresses 
this problem by analyzing the results of experiments based on progressive or very partial 
lesions of the nigrostriatal DA pathway in the rat. 
www.intechopen.com
 
Neuroscience – Dealing with Frontiers 
 
254 
4.2 Experimental observations 
To address this issue, partial and progressive destruction of the dopaminergic terminals of 
the STR was achieved and various biochemical parameters were monitored. The injections 
were not directly located in the striatal tissue but in the lateral ventricle. Recurrent 6-OHDA 
injections were administered week after week, locally in the rat STR. In these lesioned rats, 
metabolic alterations of DA were followed along with the kinetic parameters of the uptake 
process in synaptosomal preparations. These parameters (apparent Km and Vmax) are 
correlated with the number of uptake sites determined in binding experiments with a ligand 
of the DAT carrier protein, GBR12935. The possible role of GLU neurotransmission in these 
alterations was also investigated. 
Neither behavioral disturbance nor loss of weight was observed during treatment. 
Following successive injections, however, progressive biochemical alterations developed in 
both the median and lateral part of the STR, ipsilaterally to the injected ventricle.  
Control values for tissue DA were 54.99.3 ng/mg prot and 45.76.9 ng/mg prot for the 
median and lateral STR respectively. For tissue DOPAC, the control values were 27.193.6 
ng/mg prot and 26.44.11 ng/mg prot in the median and lateral STR respectively. The first 
changes observed were in tissue DA, which began to decrease after the first two injections, 
reaching only 23.3 and 29.6% (median and lateral STR respectively) of the values of the 
sham-injected animals after the 8th injection (Fig. 9). The decrease in tissue DOPAC was  
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Fig. 9. Tissue DA, DOPAC and TH (left). Mean TH activity indexed by DOPAC/DA ratio 
(Right). 
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slower, reaching 45.5 and 52.7% (median and lateral STR respectively) of the controls after 
the 8th injection. The tissue DOPAC/DA ratio (0.494 in the control rats) increased 
significantly only after the 6th injection, reaching a value of 1.4 in the median part of the STR 
after the 8th injection (Fig. 9). The tissue content of TH (Fig. 9) decreased very slowly and 
the differences compared with control rats (8.940.60 UTH in the median STR; 9.240.81 
UTH in the lateral STR) were only significant after the 8th injection (63 and 84.4% of controls 
in the median and lateral STR respectively). These alterations were first detected in the 
medial part of the STR (in the more lesioned part) and 2 weeks later, more laterally. Thus an 
immediate alteration of tissue DOPAC and DA was observed, followed by a delayed 
increase in the DOPAC/DA ratio and a late reduction in the amount of TH. 
Binding of [3H]GBR12935 was measured in synaptosomes prepared from rats that had been 
injected for 8 weeks. The  Bmax in the sham-operated group was 3.82 pmole/mg prot. In the 
lesioned group, Bmax fell to 2.31 pmole/mg prot (60.4%) but returned to 3.42 pmole/mg prot 
in lesioned animals treated daily with MK801 (89.5% of sham-operated group). The ability 
of synaptosomes to load [3H]DA was not greatly affected in lesioned animals. The slopes of 
the [3H]DA accumulation curves were: 0.101 pmole/mg prot/min for the sham-operated 
animals, 0.089 pmole/mg prot/min  for the lesioned group (88.6% of the sham-operated 
group, n.s.) and 0.098 pmole/mg prot/min  for the lesioned animals treated with MK801 
(97.1% of the sham-operated group, n.s.) (Fig. 10). However, the ratio between [3H]DA 
accumulation and [3H]GBR12935 binding (in pmol/pmol of [3H]GBR12935/min, data not 
shown) was 0.026 (100%) for the sham-operated animals, 0.038 for the lesioned group 
(146.5%; P<0.05) and 0.028 for the lesioned animals treated with MK801 (108.5% of the 
sham-operated group, n.s.).  
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Fig. 10. Lineweaver-Burk plot of [3H]DA capture in striatal synaptosomes  
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The apparent Km and Vmax  of the [3H]DA transport reaction were calculated by linear 
regression (Fig. 10). The slopes of the curves obtained for lesioned-only animals and 
lesioned plus MK801-treated animals were both significantly different from that of sham-
operated animals (P<0.05). The values of Vmax were 2.967, 0.382 and 0.824 pmole/mg 
prot/min respectively for sham-operated, lesioned and lesioned + MK801-injected rats. The 
Km values were 0.78, 0.13 and 0.27 µM respectively. 
4.3 Nigrostriatal lesion reduces DA uptake but increases DA transport 
The reduction in the levels of tissue DA and DOPAC appeared soon after the first injection. 
The DOPAC/DA ratio, reflecting TH protein activity (Lavielle et al., 1978; Bannon & Roth, 
1983; Zetterström et al., 1988; Nissbrandt et al., 1989; Soares da Silva & Garret, 1990), and the 
amount of TH protein in the tissue remained unchanged during the first 6 weeks. This 
reduction in intraterminal DA stores that is not associated with changes in DA synthesis is 
consistent with the observations that we report below of increased basal DA release during 
the very early phases of denervation (Dentresangle et al., 2001; Dzahini et al., 2010).  
After six and eight injections, both the tissue DA and DOPAC continued to decrease and 
tissue levels of TH protein began to decline. In contrast, the DOPAC/DA ratio increased, 
confirming a delay in increased DA synthesis. This could be the result of decreased 
intraterminal DA. TH activity is under the control of cytoplasmic amine levels through an 
end-product regulatory process (Ames et al., 1978; Mann and Gordon, 1979; Zigmond et al., 
1989; Fillenz, 1993). Therefore increased TH activity, which is often reported after partial 
lesion of the DA pathway (Zigmond et al., 1990) could be, at least in part, a consequence of 
reduced intraterminal DA pools. The simultaneous reduction in the amount of tissue TH 
protein may occur in one of two ways: (1) a reduction in the number of DA terminals, or (2) 
increased protein turnover associated with the increased catalytic activity (Vrana and 
Roskoski, 1983; Lavergne et al., 1994).  
This set of results is consistent with the hypothesis that the preservation of extracellular DA 
after partial destruction of the nigro-striatal DA pathway is due to activation of basal DA 
release. However, as already mentioned, this is unlikely to be the result of electrical 
activation of DA neurons in the SNc. Thus, alterations in DA transport at the level of the DA 
terminals in the STR are more likely. 
The amplitude of the denervation produced by eight injections of the toxin was evaluated 
initially. The amount of TH protein and the binding of transport sites are considered to be 
valid indices of DA pathway denervation (van Horne et al., 1992; Maloteau, 1998). In the 
present experiment, tissue TH protein levels were reduced to 63% of the levels found in 
controls, and the Bmax of [3H]GBR12935 was reduced to 60.4% of the value found in sham-
operated animals. Thus, about 40% of DA terminals may have degenerated after eight 
injections of the toxin. 
Given this 40% reduction in the number of binding sites in the synaptosomal preparation of 
lesioned rats, the kinetic parameters of the DA uptake process are apparently paradoxical. 
First, the global DA uptake was only reduced by 11% (insignificant decrease), and when 
adjusted according to the number of sites (reduced by 40%), it was actually increased (146% 
of controls). This observation suggests an increase in the efficiency of the transport process, 
compensating for the reduction in the population of DA terminals. Second, the Vmax, which 
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is an index of transport capacity, was only 12% of the value in control rats. This observation 
shows that a large number of sites, still bound to [3H]GBR12935, had become unable to carry 
DA. Third, it can be concluded from the low Km value that the affinity of DA for the carrier 
protein had increased. These results strongly suggest that moderate DA denervation of the 
STR results in a reduction in the number of functional DA transporters able to carry DA, but 
an increase in their affinity, which is responsible in turn for an increased rate of transport. 
We will see below that a new way to see the structure of the DAT protein could underline 
this paradoxical data. Indeed DAT is no longer considered as only an uptake processor but 
rather as a dual actor of the DA transport regulating extracellular DA homeostasis.  
5. Presynaptic GLU – Induced activation of DA release in the STR after partial 
nigral lesion 
The behavioral and biochemical recovery, after partial unilateral lesion, of the dopaminergic 
nigrostriatal path has been reported in various species from rodents to primates (Hefti et al., 
1985; McCallum et al., 2006; Boulet et al., 2008; Perez et al., 2008). This recovery is thought to 
result from normalization of the extracellular dopamine (DAext) in the STR that was initially 
reduced by the lesion (Robinson and Whishaw, 1988; Castaneda et al., 1990; Zigmond et al., 
1990; Emmi et al., 1996). However, it remains unclear whether this compensation results 
from overactive nigral neurons, as is proposed to occur after LevoDOPA treatment (Grace, 
2008), from direct preterminal influences in the STR (Dentresangle et al., 2001), or from both. 
A role for GLU  in this phenomenon has been proposed given that the GLU tone increases in 
various regions of the basal ganglia following SNc lesions, including in the STR (Calabresi et 
al., 1993; Cepeda et al., 2001; Tang et al., 2001), the SNc (Turski et al., 1991; Bezard et al., 
1997) and the subthalamic nucleus (Benazzouz et al., 1993; Amalric et al., 1995; Phillips et al., 
2006). This was confirmed by the fact that behavioral and biochemical recovery were 
inhibited by chronic treatment with GLU receptor (GLUR) antagonists including MK801 (see 
the preceding paragraph) and 3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1-phosphonic 
acid (CPP) (Emmi et al., 1996). The nature of the mechanisms evoked by GLU remains 
unclear however, because compensatory mechanisms occur very early or following very 
partial lesions, at a stage at which the spontaneous activity of midbrain DA neurons was not 
found to be altered (Hollerman and Grace, 1990) and when the impulse/release ratio in the 
terminal region appeared unchanged (Dentresangle et al., 2001). To complicate the situation, 
it is now well known that GLU can enhance DA release independently from the 
spontaneous electrical activity of the midbrain DA neurons (Leviel et al., 1990; Keefe et al., 
1992; Olivier et al., 1995, 1999). 
5.1 Experimental observations 
To understand the functional link between DA and GLU during the compensatory process a 
very partial and laterally located lesion of the SN was produced in rats using 6-OHDA. 
Three weeks after this lesion, it was possible to compare the metabolic consequences of a 
large denervation in the lateral part of the STR with those in a medial region spared by the 
denervation. Cartography of the tonic extracellular DA and DOPAC concentration was 
performed using in vivo voltammetry. In rats with similar lesions medial and lateral 
microdialysis approaches allowed us to measure the extracellular GLU concentration. The 
effect of GLU antagonists (amantadine, memantine and riluzol) on neurotransmission and 
their neuroprotective action on tonic DA enhancement were also tested. 
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Fig. 11. Lateral lesion of the SN and its consequences for striatal DA denervation and release 
Cartography of the STR using voltammetry 
The STR was stereotaxically explored in one coronal plane (8.2 mm anterior to the ear axe) 
to localize biochemical changes in vivo. Figure 11 shows the extracellular concentrations of 
DA expressed in nM and as the ratio (in %) between values obtained in lesioned and control 
animals in each homologous striatal area for each subregion explored. In the lesioned 
animals, DA measured in the intact median region (lat. 2) showed a notable increase (352%, 
p< 0.001) in comparison with control values. This effect was less pronounced in the 
intermediate and lateral striatal areas (lat. 3–4) but was nevertheless present. In the most 
completely DA-deafferented striatal regions, DA levels did not differ significantly from 
control values, being only slightly higher. In contrast, the extracellular level of DOPAC 
decreased enormously (26% of control values; p< 0.001) in the lateral part of the STR in 
comparison with values detected in the homologous striatal region of the control group. In 
the medial region DOPAC concentrations remained poorly affected (Dzahini et al., 2010). 
Effects of partial lesions of the SN and microdialysis results  
Voltammetry furnishs excellent stereotaxic localization of biochemical alterations but the 
use of pargyline to detect DA could produce a bias in the measurements. To better quantify 
the changes observed with voltammetry, and to extend the measurements to amino acids, 
the medial spared region was implanted with a microdialysis probe, and superfusates were 
subjected to HPLC and two analyses, one for catecholamines and the other for amino acids. 
In sham-operated and untreated rats, the spontaneous extracellular concentrations of DA 
(7.28±0.36 nM), DOPAC (9.19±1.1 µM), HVA (6.54±0.59 µM), GLU (10.0±0.27 µM), GABA 
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(0.42±0.06 µM) and ASP (0.47±0.05 µM) were in the range of previously reported values. 
Importantly, DA was in the nano molar range in the extracellular space whereas metabolites 
and amino acids were in the micro molar range. Three weeks following the lesion in the 
lateral part of the SN, an increase in DA was detected in the medial STR (29.2±0.28 nM). 
Simultaneously an increase in GLU was observed (24.4 ± 0.75 µM). In contrast, the DA 
metabolites, DOPAC (10.8±0.10 µM) and HVAext (8.86±0.90 µM), remained unchanged. 
Likewise, GABA (0.63±0.17 µM) and ASP (0.47±0.05 µM) were not significantly altered.  
 
Fig. 12. Tissue DA and amino acid in the striatum 3 weeks following lesioning of the SN 
using 6-OHDA 
Treatment of lesioned rats with GLU antagonists 
Treatment with chronic memantine, amantadine or riluzol seemed to counteract the tonic 
increase in DA induced following the lesion that was observed via voltammetry and 
confirmed using microdialysis (Fig. 12). Only a moderate increase in DA persisted following 
chronic amantadine administration (12.4 ± 1.26 nM versus 7.28 ± 0.36 nM in controls). The DA 
concentration remained at basal levels following treatment with memantine and riluzol (Fig. 
12). Acute treatments with the same substances were less efficient at counteracting the increase 
in DA but the same trends were apparent (15.1 nM, 24.1 nM and 24.4 nM respectively for 
memantine, amantadine and riluzol versus 29.2 nM in the controls, Dzahini et al., 2010). The 
GLU antagonists did not interact with the DA metabolites DOPAC and HVA. The results are 
presented in Fig. 12 as percentages of the values obtained in lesioned rats. 
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The extracellular GLU concentration increased tonically after the lesion (24.4±0.75 µM 
versus 10.0+0.27 µM in controls). This effect was counteracted by treatment with either 
chonic or acute memantine (47.1±2.3 µM and 27.1±1.53 µM respectively). Chronic riluzol 
also counteracted the lesion-induced increase in GLU after chronic application (21.8±0.68 
µM) and acute riluzol drastically reduced GLU (0.7±0.05 µM). GLU was also reduced after 
both chonic and acute amantadine treatment (1.04±0.4 µM and 0.74±0.26 µM respectively). 
No alterations in GABA or ASP were detected in response to the treatment of lesioned rats 
with GLU antagonists. The results obtained after chronic treatments are presented in Fig. 12 
as the percentage of values obtained in lesioned rats. The results obtained after acute 
treatments are presented elsewhere (Dzahini et al., 2010). 
Substantially, the lesion produced a large increase in DA and GLU in the medial STR that 
was not accompanied by noticeable alterations in the two DA metabolites or the other two 
amino acids that were measured. The three treatments with GLU antagonists seemed to 
affect DA metabolism in the same way, counteracting the lesion-induced increase in DA. 
These treatments had differential effects on GLU. 
Twenty-one days after the lesion, the denervated part of the STR (lateral) exhibited 
biochemical responses previously described after high levels of DA cell depopulation: a 
drastic reduction in DOPAC and an unmodified or slightly increased DA (Zigmond et al., 
1984; Altar et al., 1987). In contrast, a large increase in DA (two- to three-fold) and a modest 
alteration in DOPAC was observed using voltammetry and confirmed using microdialysis 
in the spared part of the STR  (medial). In this case, the levels of DA probably resulted from 
permanent (tonic) enhancement of the spontaneous release of DA. It has been shown that 
partial lesions leave the stimulation/release ratio unmodified (Dentresangle et al., 2001). A 
much larger lesion of the DA cell population seems to be required to alter the spontaneous 
pattern of discharge of nigral DA cells (Hollerman and Grace, 1990; Harden and Grace, 
1995) or stimulation-induced DA release (Stachowiak et al., 1987). These observations 
strongly suggest that after lateral SN lesion, a global process activates tonic DA release by an 
indirect mechanism acting presynaptically in the STR. 
It has been claimed that recovery of the DA in the STR after partial lesions of the SN could be 
related to alterations in GLU neurotransmission (Calabresi et al., 2000; Emmi et al., 1996; 
Kashani et al., 2007). However, the mechanism and the location of this alteration remain 
unknown. We found that 3 weeks after the lesion, GLU was clearly enhanced in the medial 
STR. When GLU neurotransmission was pharmacologically interrupted by specific GLU 
blockers (riluzol, memantine and amantadine), a reduction in extracellular GLU activation was 
observed, with a simultaneous reduction in the tonic DA increase induced by the nigral lesion. 
Amantadine and memantine were proposed to have some neuroprotective effects after 
discovering the importance of NMDA receptor-mediated excitotoxicity as a factor 
underlying neurodegeneration in Parkinson’s disease (Greenamyre and O’Brien, 1991). 
Indeed antagonists of NMDA receptors have been shown to inhibit neurodegeneration of 
the DA system induced by MPP+ and methamphetamine (Sonsalla et al., 1989; Turski et al., 
1991). In our case, the effect of the two GLU antagonists was to counteract the increase in 
GLU and DA induced by the nigral lesion. Several studies have suggested that NMDA-
induced DA release could be the main regulatory mechanism of extracellular DA (Bannon et 
al., 2001; Leviel, 2001; Mortensen and Amara, 2003), and our observations are consistent 
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with the hypothesis of a NMDA-induced mechanism causing stable dopaminergic hypertony. 
The effects of riluzol strengthen this hypothesis. First proposed to inhibit GLU release (Mantz, 
1992), its action has also been attributed to persistent blockade of the sodium current (Del 
Negro, 2005). In our hands, riluzol reduced the release of GLU in sham-operated animals and 
counteracted the lesion-induced GLU and DA as well (Dzahini et al., 2010). 
6. Conclusions: DA/GLU, a deleterious partnership? 
To summarize the present results and referenced data, the most original outcome is that DA 
release in the STR is not simply a readout of activity in DA neurons that provide a diffuse 
DA tone in the extracellular space. Rather, DA can be released by at least two different 
mechanisms with different kinetics, locations and regulatory processes. Based on the data 
reported here, a working hypothesis can be proposed: that a weak reduction in the DA cell 
population in the SNc leads to metabolic alterations in the STR that result in further death of 
DA terminals in this region. The development of this process could follow three major steps 
(Fig. 13): 1) the activation of diencephalic structures, thalamic or sub-thalamic nuclei that  
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Fig. 13. A working hypothesis of the mechanism involved in the presymptomatic phase of 
PD 
project toward cortical regions; 2) in turn, a tonic increase in some of the corticostriatal 
pathways that we know to be responsible for different controls of the striatal GABA neurons 
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and DA terminals; 3) indirect activation through GLU afferents to DA terminals of tonic DA 
release, which initially constitutes autotherapy allowing the behavioral compensation 
observed in Parkinson’s disease. However the toxic effect of DA on the DA terminal 
(production of H2O2 when present in excess) could constitute a secondary pathological 
agent, maintaining the degenerative process. Each of the three steps mentioned here require 
further elucidation and demonstration, but a large set of data in each case is consistent with 
this hypothesis. 
DA homeostasis constitutes one of the functions of the DAT via DAT-RT. This is under the 
control of many regulatory processes including tonic GLU neurotransmission. Experiments 
regarding the consequences of partial lesions seem to indicate a role for this GLU-dependent 
regulation in the tonic DA overflow and in maintaining a permanent excess of extracellular 
DA. It remains to be determined how local GLU can induce the presynaptic and tonic 
activation of DA release. This could be achieved directly through GLU receptors located on 
DA terminals or indirectly through heterologous neurotransmission systems such as GABA 
or ACH. 
7. Technical procedures 
7.1 Animals 
Male Wistar rats (Iffa-Credo France) weighing 250 g were used in the studies reported here. 
They were maintained and sacrificed in accordance with the European Communities 
Council Directive (86/609/EEC).  The animals were anesthetized with 1.5% isoflurane in 
pure oxygen in air or were injected with chloral hydrate (400 mg/kg) and spontaneously 
inspired (Leviel et al., 1989; Olivier et al., 1995). When necessary they were placed in a 
stereotaxic device. For the short interventions (less than 1 hour), a mixture of 
ketamine/rompun was used (150/10 mg/Kg). Rectal temperature was maintained at 38 °C. 
Cardiac and respiratory rhythms were continuously monitored. 
7.2 Lesions of the lateral SN 
The lateral part of the SN was unilaterally injected with a solution of 6-OHDA (3 µg free 
base in 1 µl isotonic saline containing 0.2% ascorbic acid, pH 4). The stereotaxic coordinates 
were, in mm: Ant.: 3.5, Lat.: 2.5 and Ht.: 3.4. The horizontal plane passed through the 
interaural axis and incisor bar. Unlesioned rats were only submitted to nigral injection of the 
vehicle (Dentresangle et al., 2001; Dzahini et al., 2010). 
7.3 Surgery and procedures for recurrent ventricular injections 
Animals were anesthetized with ketamine (150 mg/Kg; Panpharma), maintained in a 
stereotaxic device and implanted with a cannula (0.71 mm o.d. with a removable mandrel) 
in the anterior part of the left lateral ventricle. The head of the cannula was sealed with 
acrylic cement, embedding screws set in the cranial bone. The stereotaxic coordinates were 
the following (in mm): AP: 0.48; LM: 1; H: 6 from the bregma (following Paxinos and 
Watson, 1986). Rats were allowed to recover for 2 weeks. In order to inject 6-OHDA (30 min 
after administering 25 mg/kg imipramine i.p. to protect noradrenergic neurons), the 
mandrel of the cannula was removed and replaced by an injector connected, through a thin 
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catheter, to a microsyringe. Weekly injections of 10 µl  of a solution (0.1% ascorbic acid in 
0.9% NaCl) with or without  35 µg of 6-OHDA were given to awake and freely moving 
animals. Four groups of 12 animals received 2, 4, 6 or 8 weekly injections of the toxin (n=6) 
or the toxin vehicle only (n=6). A fifth group (n=6) of rats received 8 weekly injections of the 
toxin and a daily injection of 2 mg/kg MK801 (i.p.). 
7.4 Medial Forebrain Bundle (MFB) stimulation 
A bipolar electrode was implanted in the medial forebrain bundle (MFB) containing the DA 
ascending fibers (coordinates: A:5; L:1.3; Ht:2). Every 4 minutes, the MFB was stimulated for 
20 seconds by 20 bursts (one per second) of 25 positive square pulses, each lasting 0.5 ms, 
with a 2 ms interpulse interval (40 Hz theoretical frequency). Each burst was triggered 300 
ms after the measurement of DPA (Dentresangle et al., 2001; Dzahini et al., 2010). 
7.5 Voltammetric investigations 
Difference Normal Pulse Voltammetry (DNPV) and Differential Pulse Amperometry (DPA) 
were performed using treated carbon fiber electrodes produced as described previously 
(Olivier et al., 1995; Dentresangle et al., 2001). Their active part was the surface of one 
pyrolytic carbon fiber (SOFICAR, France), 250 µm long and 8 µm in diameter. A stainless 
steel tweezer fixed on the interaural bar was used as an auxilliary electrode and the 
Ag/AgCl reference electrode was a silver wire coated with AgCl. This was maintained in 
contact with the skull by means of a sponge moistened with Phosphate Buffer Saline (PBS) 
solution (PBS, pH 7.4). The three electrodes were connected to a pulse voltammetric system 
(Biopulse, SOLEA Tacussel, France). Carbon-fiber electrodes were electrochemically treated 
as previously described (Gonon et al., 1984). To calibrate the electrodes, voltammograms 
were recorded in vitro in a standard solution of DOPAC or DA and ascorbic acid in PBS. The 
values of the oxidation potentials and the amplitude of the peaks were stabilized after 4–5 
successive scans (10 to 15 min). Their values were 60 mV for ascorbic acid, 60 mV for 
DOPAC and 90 mV for DA. It had previously been verified that the amplitude of the 
oxidation peak for these substances is linearly correlated with their concentrations. The 
oxidation potentials for DA and DOPAC were however too close to be properly 
differentiated in vivo and DA was three orders of magnitude lower than DOPAC. Thus, for 
adequate detection of DA, DOPAC formation was inhibited by pretreatment with pargyline 
(75 mg/kg, i.p.), an inhibitor of monoamine oxidase. 
7.6 Superfusion procedures (microdialysis & push-pull cannula) 
Animals were submitted to superfusion of the striatum to analyze extracellular DA, DOPA, 
HVA, GLU, GABA and ASP (Dzahini et al., 2011). They were implanted with a dialysate 
probe (250 µm in diameter and 4 mm length, cut off 6000 dalton, CMA, Sweden) in the 
anterior part of the caudate nucleus (Ant.: 8.4 mm; Lat.: 2.5 mm; H.: 6 mm, same stereotaxic 
references). The cannula was supplied (1 µl/min) with an artificial CSF (in mM, 145 NaCl, 
2.7 KCl, 1.0 MgCl2, 1.2 CaCl2, 0.45 NaH2PO4, 2.3 Na2HPO4, adjusted to pH 7.4).  
Push-pull cannulae were used in an experiment devoted to measuring the radioactive form 
of DA and DOPAC (Leviel et al., 1989, 1990, 1991). The cannulae (1.0 mm outer diameter) 
were supplied (flow rate: 12.5 µl/min) with an artificial cerebrospinal fluid (CSF) adjusted to 
pH 7.4 with an O2-CO2 (95:5 v/v) mixture. 3,5-[3H]TYR (50 Ci/mmole, Dositek, France) was 
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purified by high performance liquid chromatography (HPLC) on a C18 Microbondapak 
column (Millipore-Waters, France) using H3PO4 (1 mmol/l, pH 3) as a mobile phase. 
[3H]TYR was added to artificial CSF (80 µCi/ml) 1 hour after implantation and superfusates 
were collected thereafter as successive 20 minute fractions. 
7.7 Biochemical analysis 
Dialysates collected for measuring catecholamines were protected with 5 µl perchloric acid 
(0.05 M) and immediately underwent HPLC analysis. Dialysates collected for amino-acid 
analysis were maintained at -80 °C and kept frozen until analysis. 
The catecholamines DA, DOPAC and HVA were measured in the collected fractions by 
electrochemical detection with the potential of the working electrode maintained at 0.7 V 
(Antec-Decade) after HPLC separation (column C18 Brownlee RP18, 5 µm, 2.1 x 220 mm, 
maintained at 32 °C; Mobile phase: 50 mM KH2PO4, 0.1 mM EDTA-Na2, 0.28 mM sodium 
octyl sulfate, 6% methanol, adjusted to pH 4.5; flow rate 0.25 ml/min). Catecholamine peaks 
were identified based on their retention times (Olivier et al., 1995; Dzahini et al., 2010). 
Extracellular catecholamine concentrations were estimated by evaluating the peak areas of 
each substance and their respective external standard (analytical software AZUR, Datalys 
France). The running time for each determination was 25 min.  When superfusion was 
conducted with 3,5-[3H]TYR added to the CSF, the radioactivity corresponding to each 
HPLC peak was counted using a continuous flow scintillation detector (Packard-
Radiomatic, Flo-One B A250)( Leviel et al., 1989, 1990, 1991). 
The concentrations of the amino acids GLU, GABA and ASP in the dialysates were 
determined after HPLC, via laser-induced fluorescence detection (Dzahini et al., 2010). 
Briefly, 2 µl of sample or standard was derivatized with naphthalene-2,3-dicarboxaldehyde. 
The resulting mixture was automatically loaded onto a Symmetry Shield-C18 reverse-phase 
column (100_2.1 mm, 3.5 _m particle size; Waters, Milford, MA), using a refrigerated 
Triathlon auto injector (Polymer Laboratories, Marseille, France). The mobile phase 
consisted of 0.04 M NaH2PO4, pH6, in a 3–50% acetonitrile gradient. The flow rate was 0.35 
ml/min, maintained using two Shimadzu (Kyoto, Japan) LC 10AT pumps. Amino acid 
peaks were identified based on their retention time. Extracellular amino acid concentrations 
were estimated by evaluating the peak areas of each amino acid and their respective 
external standard (analytical software class LC10; Shimadzu). The running time for each 
determination was 12 min. 
7.8 DA and DOPAC tissue concentration 
At the end of each experiment, to verify the location of the cannula, the animals were 
intracardially perfused with a 4% formaldehyde solution, after which the brain was 
removed, sliced (50 µm) and stained with cresyl violet. 
Protein weights were measured using the micro BCA Protein Assay (Pierce, Biorad). 
The homogenate (20 µl) was mixed with 20 µl of 0.3 N perchloric acid containing 0.8 mM 
EDTA, added to an internal standard (3,4-dihydroxybenzylamine) and centrifuged (10,000 
g, 10 min). The supernatant of each sample (10 µl) was injected into a C18 reverse-phase 
microcolumn (Spheri5, RP-18, 220  2.1 mm, Browlee labs). The mobile phase consisted of 40 
mM KH2PO4 (pH 4.5), 0.26 mM octane sulfonic-acid, 15 mg/l EDTA and 11% methanol 
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(vol/vol), and the flow rate was 0.20 ml/min. The liquid chromatography system (TSP) was 
coupled to an electrochemical detector (Millipore) with a working electrode set at 0.8 V. The 
concentrations of DA and its metabolites in CP were calculated for each sample (in ng/mg 
prot). The results were normalized by expressing the changes in DA and DOPAC levels as 
percentages of the values obtained in control animals (Dentresangle et al., 2001).  
7.9 Preparation of synaptosomes  
The method for synaptosomal preparation and measurement of [3H]DA uptake was 
modified from Masserano et al. (1994). Rat brains were rapidly removed and chopped into 
1.6-mm-thick slices, in the sagittal plane corresponding to the anterior commissura. The 
median part of the CP, ipsilateral to the injection site, was pooled for all rats of each group 
and homogenized in 25 ml cold 0.32 M sucrose (10 up and down strokes, at 850 rpm, in a 
glass-teflon homogenizer). The homogenate was centrifuged at 800 g for 10 min at 4 °C and 
the pellet was discarded. The supernatant (S1) was kept on ice until it was resuspended for 
the [3H]DA uptake or [3H]GBR12935 binding protocols.  
[3H]DA uptake: The supernatant (S1, 15 ml) was centrifuged (20,000 × g for 10 min at 4 °C), 
and the resulting pellet (P2) was resuspended in 20 ml of ice-cold incubation buffer (in mM): 
NaCl, 125; K2HPO4, 1.5; MgSO4, 1.5; CaCl2, 1.25; d-glucose, 10; HEPES, 25; ascorbic acid, 0.1; 
pargyline, 1 and EDTA, 0.1, pH 7.4. The buffer was oxygenated with 100% O2 for 10 min 
before use. The assays were performed in triplicate with 400 µl of pellet resuspended in 1 ml 
of incubation buffer. After preincubation of 3 min at 37 °C, the assays were initiated by 
adding 10 µl of increasing concentrations of [3H]DA (10, 20, 40, 50, 100, 200, 400 nM) for 7 
min at 37 °C. Nonspecific values were determined in the presence of Mazindol (1 µM) for 7 
min at 4 °C. Assays were terminated by immediate filtration using Whatman GF/B filters 
soaked in 0.32 M ice-cold sucrose containing 0.05% polyethylenimine. Filters were washed 
three times with 3 ml of 0.32 M ice-cold sucrose and radioactivity was measured using a 
Packard TRI-CARB 2100 TR. The apparent Km and Vmax  of DA uptake were calculated by 
linear regression of the reciprocal plot (1/v vs. 1/S). The protein content in the resuspended 
pellet P2 was measured using the micro BCA kit (Pierce, Biorad). 
7.10 [
3
H]GBR12935 binding 
The [3H]GBR12935 binding protocol was modified from Berger et al. (1985). The supernatant 
(S1, 10 ml) was centrifuged (20,000 g for 10 min at 4 °C), and the resulting pellet (P2) was 
resuspended in 13 ml of 50 mM ice-cold Tris-HCl buffer, pH 7.7, containing 120 mM NaCl. 
Assays were performed in triplicate with 500 µl of pellet suspension and 50 mM Tris-HCl 
buffer, pH 7.7, containing 120 mM NaCl and 0.01% of Bovine Serum Albumin in a final 
volume of 2 ml. Incubation was initiated by the addition of 100 µl of [3H]GBR12935 (5 µM) 
for 45 min at 25 °C. Non-specific binding was determined in the presence of 1 µM Mazindol. 
Filters were washed three times with 4 ml ice-cold Tris-HCl 50 mM buffer pH 7.7 and 
radioactivity was counted using a Packard TRI-CARB 2100 TR. The protein content in the 
resuspended pellet P2 was measured using the micro BCA kit (Pierce, Biorad). 
7.11 Determination of TH protein content 
TH protein content was measured using a semi quantitative immunoblotting technique as 
previously described by Garcia et al. (1994). Briefly, after centrifugation of the homogenate 
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(10,000 g, 30 min), 1.5 µl of supernatant was placed onto a nitrocellulose membrane (Bio-rad 
162-147, 0.2 µm). Non-specific binding sites were saturated with 50 mM Tris buffer 
containing 2% bovine serum albumin. The protein was revealed using, in succession, a 
mouse monoclonal antibody to TH (10 ng/ml; Boehringer Mannheim), a 125I-labeled 
protein A (S.A: 1.11x 10-9 Bq/mg, 1850 Bq/ml, Amersham) and 3H-hyperfilms (Amersham). 
The radioimmunochemical labeling was calibrated using a scale of standard TH protein 
(extracted from adult rat adrenals and diluted in homogenates of cerebellum). One U of TH 
(UTH) is defined as the mean TH protein content of 10 µg (wet weight) of adult rat adrenal 
gland. Optical density measurements were converted into UTH/mg tissue by reference to 
the standards. Each reading provided the surface area (mm2) of the dot and the TH tissue 
concentration (UTH/mg tissue). Using the surface area and the TH tissue concentration, the 
amount of TH (UTH) in the region of interest was calculated and normalized by expressing 
the amount of TH as a percentage of values in the control rats. 
7.12 Immunoprecipitation of TH enzyme 
Rats were perfused transcardially with NaCl 9°/°° and PFA 4%. The brain was then removed 
and stored in PBS buffer containing 0.1% sodium azide pH 7.4 (PBSA). To evaluate the 
extent of the lesion in the SN and the extent of CPc denervation, TH immuno precipitation 
was performed on coronally sectioned slices (40–50 µm thickness). Brains were cut on a 
cryostat (HM440E, Microm); free-floating slices were collected and stored in PBSA. Sections 
were incubated in 3% H2O2 in PBS to block endogenous peroxidase activity and were then 
incubated overnight with the primary rabbit anti-TH antibody (Chemicon, Temecula, CA; 
1/2500) in 10% normal swine serum, TBS, pH 7.4, containing 2% NGS and 0.2%Triton X-100 
for 24 h at 4 °C on a platform shaker. After rinsing in PBS 0.1% plus triton X100, sections 
were incubated with biotinylated swine anti-rabbit secondary antibody for 30 min at room 
temperature. This was followed by incubation with Strept-ABC-HRP complex (Dako, 
Glostrup, Denmark). TH immunoreactive neurons were visualized using 3.3- 
diaminobenzidine (DAB) in N2+ 0.5% and H2O2. To test the specificity of the staining, control 
sections were processed in an identical manner but with omission of the primary or 
secondary antibody. All sections were then washed for 10 min in PBS, mounted on slides, 
dried, dehydrated in increasing grades of ethanol, cleared in toluene, and mounted with 
DPX and cover slipped. These sections were scanned and analyzed immediately using 
Imagemaster Labscan V-3.00 (Pharmacia Biotech, Dzahini et al., 2010). 
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